Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study by Ewertz, M et al.
Hormone use for menopausal symptoms and risk of breast cancer.
A Danish cohort study
M Ewertz*,1, L Mellemkjaer
2, AH Poulsen
2, S Friis
2, HT Sørensen
3,4, L Pedersen
3, JK McLaughlin
4,5 and
JH Olsen
2,4
1Department of Oncology, Aalborg Hospital, Aarhus University, Hobrovej 18-22, PO Box 365, DK-9100 Aalborg, Denmark;
2Institute of Cancer
Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark;
3Department of Clinical Epidemiology, Aarhus University,
Vennelyst Boulevard 6, DK-8000 Aarhus, Denmark;
4Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA;
5International Epidemiology Institute, Rockville, MD, USA
Numerous studies and meta-analyses have shown that hormone replacement therapy (HRT) for menopausal symptoms increases
the risk of developing breast cancer, estimated to be 2.3% for each year of use. The influence of different oestrogen–progestin
regimens has still not been fully evaluated. Using longitudinal data from the population-based prescription database of the county of
North Jutland, Denmark, and the Danish Cancer Registry, we examined the risk of developing breast cancer in relation to HRT in a
cohort of 78380 women aged 40–67 years from 1989 to 2002. A total of 1462 cases of breast cancer were identified during a mean
follow-up of 10 years. Use of HRT did not increase the risk of breast cancer in women aged 40–49 years. Restricting the cohort to
48812 women aged 50 years or more at entry, of whom 15631 were HRT users, we found an increased risk associated with current
use of HRT (relative risk 1.61, 95% confidence interval 1.38–1.88). The risk increased with increasing duration of use and decreased
with time since last HRT prescription, reaching unity after 5 years. No material risk difference was observed among the various HRT-
regimens. This population-based cohort study provides further confirmation that HRT increases the risk of developing breast cancer
in women aged 50 years or more.
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Numerous studies have shown that hormone replacement therapy
(HRT) with oestrogen with or without progestin for menopausal
symptoms increases the risk of breast cancer. A collaborative
reanalysis of data from 51 epidemiological studies of 52705 women
with breast cancer and 108411 women without breast cancer
demonstrated a 2.3% increase in breast cancer risk for each year of
HRT use (Collaborative Group on Hormonal Factors in Breast
Cancer, 1997). The highest risk estimates were seen for current and
recent use of long duration, with the relative risk (RR) for 5 or
more years of use being 1.35 (95% confidence interval (CI) 1.21–
1.49). More recent studies from Denmark (Tjønneland et al, 2004)
and the UK (Million Women Study, 2003) reported RR estimates
for current HRT use of 2.22 (95% CI 1.80–2.75) and 1.66 (95% CI
1.58–1.75), with evidence of lower breast cancer risk for
oestrogen-only HRT compared to combined oestrogen–progestin
HRT from these and other observational studies (Magnusson et al,
1999; Stahlberg et al, 2004). US randomised controlled trials have
reported RR estimates of 1.30 (95% CI 0.77–2.19) and 1.26 (95% CI
1.00–1.59) for combined HRT and 0.77 (95% CI 0.59–1.00) for
unopposed oestrogen (Hulley and Grady, 2004; Women’s Health
Initiative, 2002, 2004). Risk estimates tended to increase with
increasing duration of HRT use and to decrease with time since
last exposure.
We have conducted a study on HRT use in relation to the risk of
breast cancer using the population-based prescription database of
North Jutland, Denmark, which allows for a complete non-self
reported history of HRT exposure, including the specific type, to
be derived for every woman in the county.
MATERIAL AND METHODS
The study was conducted within the population of North Jutland, a
county with nearly 500000 inhabitants, representing approxi-
mately 9% of the total Danish population. The National Health
Service in Denmark provides tax supported health care for all
inhabitants, guaranteeing free access to general practitioners,
hospitals and public clinics, and refunds a variable proportion of
the costs of medication prescribed by physicians through a
computerised accounting system. In North Jutland, this accounting
system also provides prescription data to the Pharmaco-Epide-
miologic Prescription Database, which was initiated in 1989 (Gaist
et al, 1997) and by 1991 covered all pharmacies in the county. The
Database includes the civil personal registration number (a unique
number assigned to all Danish residents that encodes gender and
date of birth) of the patient, type of drug prescribed according to
Anatomical Therapeutical Chemical (ATC) Classification System
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drug). The civil personal identification number is maintained by
the Central Population Register (CPR), which updates information
on vital status (dates of death or emigration), address (date of
migration from the county), and the civil personal identification
numbers of all offspring. Thus, information on parity can be
obtained for all women since the establishment of the CPR in 1968.
From the files of the CPR, we identified 83873 women who were
40–66 years of age at any time during the period 1 January 1989 to
31 December 2002 and resident in the county of North Jutland.
These women were linked to the Danish Cancer Registry to identify
cases of breast cancer occurring through 2002. The Danish Cancer
Registry has recorded incident cases of cancer on a nation-wide
basis since 1943 with accurate and virtually complete ascertain-
ment (Storm et al, 1997). Tumours are classified according to a
revised version of ICD-7 (Danish National Board of Health, 2003),
and since 1978, also according to ICD-O (WHO, 1976). We
excluded 1444 women who had a cancer diagnosis (except
nonmelanoma skin cancer) before 1989 or before age 40 (if later
than 1989).
The remaining 82429 women were linked to the Pharmaco-
Epidemiologic Prescription Database. We excluded 1079 women
who received prescriptions for sex hormones other than those used
in HRT (ATC codes: G03B, G03G, G03H, G03X) including
androgens, during 1989–2002, and 2970 women who had used
systemic HRT before the age of 40 years. Among the remaining
78380 women, we identified 17466 who received at least two
prescriptions for systemic HRT (G03A, G03C, G03D and G03F)
from 1 January 1989 until 31 December 2002. In Denmark, there is
normally no reimbursement for oral contraceptives, but we
included women recorded with reimbursed prescriptions for oral
contraceptives, since this indicates that the hormones were given
for reasons other than contraception. Prescription of nonsystemic
HRT was not judged as HRT exposure for the purposes of the
present study.
The follow-up for breast cancer started on 1 January 1989 or at
age 40 years, whichever occurred later, and continued until the
date of breast cancer diagnosis, of cancer other than breast
(except) for nonmelanoma skin cancer), date of death, of
migration from North Jutland, or 31 December 2002, whichever
came first. Since women with only one prescription may never
have actually taken the drug, we classified such women as
nonexposed. The follow-up time was stratified according to use
of HRT in unexposed time (less than two prescriptions) and
exposed time (two or more prescriptions) (Figure 1). The exposed
time was further stratified into:
(1) recency of use (current use of HRT with less than 2 years since
last prescription, recent use with 2–5 years since last
prescription and former use with more than 5 years since
last prescription);
(2) number of prescriptions (2–4, 5–9, 10–19, and 20 or more
prescriptions);
(3) type of first prescription of HRT (oestrogen only, sequentially
combined oestrogen–testosterone derived progestin (levonor-
gestrel, norethisteron, norgestimat, desogestrel, gestoden),
sequentially combined oestrogen–progesterone derived proges-
tin (medroxyprogesteron), continuously combined oestrogen–
testosterone derived progestin (norethisteron), tibolone, and
progestins. Users contributed person-years to the appropriate
group until they received a prescription for HRT from one of
the other groups, and from that time on they contributed
person-years to a category of mixed use.
We computed rate ratios as the breast cancer incidence rate for
HRT exposure divided by the breast cancer incidence rate for
HRT prescr.
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Figure 1 Illustration of the method of calculation of exposure to HRT in the cohort of women aged 40–67 years in North Jutland county, Denmark,
1989–2002.
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age-standardised (direct standardisation in 5-year age-groups
to the age distribution in the total cohort of women) rate
ratios were calculated. In addition, we performed analyses based
on Cox proportional hazards models with age as the time scale.
These analyses were adjusted for calendar-period as a
time-dependent covariate with two levels (1989–1996 and 1997–
2002) and number of children and age at first child obtained from
the CPR as time-dependent linear variables. Tests were based on
the likelihood ratio test statistics calculated from Cox’s partial
likelihood. Confidence intervals were based on Wald’s test of the
corresponding regression parameters, that is, on the log scale for
the rate ratios. The statistical analyses were performed using SAS
version 8.02. The proportional hazards assumption of the Cox
models was tested by visual inspection of transformations of the
survival function using standard techniques.
RESULTS
In the cohort of 78380 women we identified 1462 cases of breast
cancer during a mean follow-up of 10 years (maximum 14 years).
Other details of the cohort including year of entry, number of
children, and age at first birth are presented in Table 1.
Table 1 Characteristics of the study cohort of Danish women by age at
entry
Follow-up starting
at 40 years
Follow-up starting
at 50 years
Number of women 78380 48812
Cases of breast cancer 1462 869
Mean years of follow-up 10.0 7.6
Year of entry into cohort
1989 42655 10241
1990 3135 2541
1991 2997 2677
1992 2975 2912
1993 2882 3128
1994 2815 3208
1995 2826 3300
1996 2734 3365
1997 2749 3242
1998 2612 3046
1999 2567 2848
2000 2564 2857
2001 2464 2753
2002 2405 2694
Number of children
0 7148 3928
1 9976 5907
2 35682 21662
3 18754 12385
4–5 6374 4586
6+ 446 344
Age at first birth
10–14 24 12
15–19 12664 9027
20–24 34613 22706
25–29 18045 10244
30–34 4541 2225
35–39 1220 590
40+ 125 80
Table 2 Age-specific breast cancer incidence rates per 100000 woman-years among HRT exposed and unexposed women, and rate ratios (RR) for
HRT-exposure, North Jutland county, Denmark, 1989–2002
HRT exposed Unexposed
Age (years) Person-years No. of cases Rate Person-years No. of cases Rate RR 95% CI
40–44 3427 2 58.4 179258 188 104.9 0.56 0.07–2.01
45–49 21908 37 168.9 191762 366 190.9 0.88 0.62–1.22
50–54 44163 90 203.8 150164 257 171.1 1.19 0.96–1.46
55–59 41022 123 299.8 89173 193 216.4 1.39 1.15–1.65
60–64 17453 78 446.9 38427 99 257.6 1.73 1.37–2.17
65–67 1725 17 985.6 4513 12 265.9 3.71 2.16–5.94
Table 3 Characteristics of HRT users aged 50–67 years in North Jutland
county, Denmark, 1989–2002
No. of women %
Total 15631 100.0
Year of second HRT-prescription
1989–1990 3676 23.5
1991–1992 2540 16.2
1993–1994 2784 17.8
1995–1996 2140 13.7
1997–1998 1799 11.5
1999–2000 1439 9.2
2001–2002 1255 8.0
Age at second HRT-prescription
40–44 1460 9.3
45–49 5829 37.3
50–54 6971 44.6
55–59 1210 7.7
60–64 150 1.0
65–66 11 0.1
Number of HRT-prescriptions
2–4 3327 21.3
5–9 2493 15.9
10–19 2994 19.2
20–39 4084 26.1
40–59 2230 14.3
60+ 503 3.2
Type of HRT
a
Oestrogen only 2965 19.0
Sequential oestrogen–testosterone-derived progestin
b 5652 36.2
Sequential oestrogen–progesterone-derived progestin
c 1221 7.8
Continuous oestrogen–testosterone-derived progestin
d 1356 8.7
Tibolone 97 0.6
Gestagenes only 1918 12.3
Mixed use 2422 15.5
aDetermined from first and second prescription ever.
bTestosterone-derived refers to
levonorgestrel, norethisteron, norgestimat, desogestrel, gestoden.
cProgesterone-
derived refers to medroxyprogesteron.
dTestosterone-derived refers to norethisteron.
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and unexposed to HRT by age. In comparison with the unexposed,
breast cancer incidence was nonsignificantly lower among
those exposed in the age group 40–49 years, with a relative risk
(RR) of 0.56 and 0.88 for ages 40–44 and 45–49, respectively. In
contrast, for those over 50 years of age RRs were generally
significantly elevated, ranging from 1.19 for ages 50–54 to 3.71 for
ages 65–67.
Women aged 40–49 years are likely to represent a mixture of
pre-, peri-, and postmenopausal women and may have used HRT
for a variety of reasons, not only for menopausal symptoms. To
study HRT use mainly in postmenopausal women and having no
information on menopausal status, we restricted the subsequent
analyses to the person-time contributed by women after they had
reached 50 years of age. With this restriction, the cohort was
reduced to 48812 women with 869 breast cancers during a mean
follow-up of 7.6 years (Table 1). However, we made use of the HRT
exposure information available from age 40–49 years so that, for
instance, a 50-year-old woman who had filled six prescrip-
tions from age 47 to 49 entered the cohort at this exposure level
(see Figure 1).
Of the 48812 women aged 50 years or more, 15631 or 32% had
filled two or more prescriptions for HRT. Table 3 shows that close
to half (47%) of these women began using HRT before age 50, that
more than 60% of users filled more than 10 prescriptions, and that
the most commonly used type of HRT was the sequential
combination of oestrogen and a progestin.
Among women age 50 or older, current use of HRT was
associated with a significantly increased risk of breast cancer, with
an RR of 1.61 (95% CI 1.38–1.88), adjusted for calendar period,
number of children and age at first birth (Table 4). The risk
increased with increasing duration of use estimated by the number
of prescriptions filled, with RR¼1.86 (95% CI 1.54–2.25) for 20 or
more prescriptions, and decreased with time since last HRT
prescription, returning to baseline after 5 or more years.
Elevated risks were observed for oestrogens alone, progestins
alone, mixed use, and sequential preparations of oestrogen and
testosterone derived progestin, while the risk was not increased for
sequential preparations of oestrogen and progesterone derived
progestin, continuous combined therapy, and for tibolone.
However, each of the latter estimates was based on fewer than 15
cases. A total of 790 women had at least one prescription for
tibolone, but since tibolone is mostly prescribed when more
conventional HRT is tolerated poorly, tibolone use is therefore
generally included in the category of mixed use. When the category
of mixed use was split into those with at least one prescription for
tibolone (eight breast cancers in 2492 person-years) and those
without tibolone (132 breast cancers in 40894 person-years),
adjusted RR estimates were 1.37 (95% CI 0.68–2.75) and 1.51 (95%
CI 1.25–1.84) respectively.
DISCUSSION
The breast cancer findings of the present population-based cohort
study are consistent with those of prior observational studies of
HRT (Collaborative Group on Hormonal Factors in Breast Cancer,
1997; Million Women Study, 2003; Tjønneland et al, 2004). RR
estimates from randomised controlled trials tend to be lower than
those from observational studies for both combined and
unopposed HRT (Hulley and Grady, 2004). If, as indicated by
the Women’s Health Initiative (2004), unopposed HRT does not
increase the risk of breast cancer, then the increased RR estimate
for unopposed oestrogen in the present study may reflect
uncontrolled bias inherent in observational studies of HRT.
Similar bias should be present for all HRT regimens, and thus it
is noteworthy that no material difference was observed among RR
estimates for the various HRT regimens.
The strength of this study is that it was conducted in a well-
defined geographical area for which standardised popu-
lation-based information is available on both exposure and
disease. The data on exposure provide a full history of prescrip-
tions for HRT during follow-up, including specific information
on HRT formulation. We are confident the exposure information
Table 4 Breast cancer risk associated with HRT-use among women aged 50–67 in North Jutland county, Denmark, 1989–2002
No. of cases Person-years Age-stnd. rate
a SRR
b Min. adj. RR
c 95% CI Fully adj. RR
d 95% CI
Unexposed 561 282.278 200.4 Ref. Ref. Ref.
HRT
2+ prescriptions 308 104.362 283.9 1.42 1.39 1.21–1.60 1.40 1.22–1.61
Recency of HRT-use
d
Current use (o2 years since last prescription) 222 67.224 331.8 1.66 1.60 1.37–1.88 1.61 1.38–1.88
Former use (2–5 years since last prescription) 55 22.540 243.6 1.22 1.13 0.85–1.49 1.15 0.87–1.51
Former use (5+ years since last prescription) 31 14.598 212.4 0.77 0.87 0.61–1.23 0.89 0.62–1.28
No. of HRT-prescriptions
2–4 52 24.262 215.5 1.08 1.06 0.80–1.41 1.08 0.81–1.43
5–9 46 20.471 232.3 1.16 1.12 0.83–1.52 1.13 0.84–1.53
10–19 63 25.184 248.8 1.24 1.23 0.95–1.59 1.23 0.95–1.60
20+ 147 34.445 348.7 1.74 1.86 1.54–2.24 1.86 1.54–2.25
HRT-type
e
Oestrogen only 50 17.888 260.4 1.30 1.29 0.97–1.73 1.35 1.01–1.80
Sequential oestrogen–testost.-derived progestin 80 25.740 317.8 1.59 1.53 1.21–1.93 1.52 1.21–1.93
Sequential oestrogen–progest.-derived progestin 6 5.062 104.2 0.52 0.58 0.26–1.29 0.57 0.26–1.28
Continuous oestrogen–testost.-derived progestin 13 5.851 224.0 1.12 0.99 0.57–1.72 0.99 0.57–1.72
Tibolone 1 509 141.4 0.71 0.86 0.12–6.14 0.84 0.12–5.95
Progestins only 18 6.441 305.5 1.52 1.42 0.89–2.28 1.36 0.87–2.24
Mixed use 140 42.871 307.5 1.53 1.50 1.24–1.36 1.51 1.25–1.82
aIncidence per 100000 person-years. Direct standardisation to studybase.
bStandardised rate ratio.
cCox proportional hazards model, adjusted for calendar period.
dCox
proportional hazards model, adjusted for calendar period and number of children and age at first birth.
eHRT-type is determined from 1st prescription, a prescription from any
other group causes transfer to mixed use group.
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population to consult doctors or purchase prescription drugs
outside their own county, and HRT is available in Denmark by
prescription only. In a study of validity of self-reported use of HRT
95% of Danish nurses registered in the prescription database as
being prescribed HRT, reported having complied with the
treatment (Løkkegaard et al, 2004). Breast cancer ascertainment
can also be regarded as almost complete (Storm et al, 1997). We
were able to control for potentially confounding effects of number
of children and age at first birth through complete registry-based
information on these variables. Social status might also be
considered to be a potential confounder since breast cancer is
associated with high socioeconomic status (Danø et al, 2003), but
in Denmark no substantial socioeconomic gradient in HRT use has
been detected (Olesen et al, 2004).
Limitations of our study include the lack of information on such
potentially confounding factors as age at menopause and body
mass index (BMI). Overall, among women aged 40–49 years, we
did not detect an increased breast cancer risk associated with HRT
use, which may well be due to the fact that these women represent
a mixture of pre-, peri-, and postmenopausal states. Despite the
lack of control for age at menopause, our risk estimate of RR¼1.61
(95% CI 1.38–1.88) for current HRT use in women aged 50 years
or more agrees well with that reported for postmenopausal women
from the Million Women Study (2003) (RR¼1.66 (95% CI 1.58–
1.75)). Several studies have found an interaction between HRT use
and BMI, the risk associated with HRT (Huang et al, 1997; Million
Women Study, 2003) being higher in lean than in overweight
women. Our study cannot address the issue of interaction between
HRT use and BMI, and our inability to control for BMI may have
led to underestimation of risks associated with HRT use.
With regard to the different types of HRT, our results were
similar to those reported in the Million Women Study and a recent
Danish study (Stahlberg et al, 2004) for oestrogen only and for less
than 5 years use of sequential preparations of oestrogen and
testosterone derived progestin. The risk associated with use of
tibolone was not materially different from other types of HRT. Our
findings of no increased risk for sequential preparations of
oestrogen and progesterone derived progestin and continuous
combined therapy are somewhat surprising, but since these
estimates were based on fewer than 15 cases, chance cannot be
ruled out as an explanation.
In conclusion, this study reports elevated risk estimates
for breast cancer with HRT use in women over age 50 years,
increasing with duration of use, and with no evidence of increased
risk 5 years after stopping HRT. Risk did not differ markedly
for treatment with oestrogen alone, progestins alone, or combi-
nations thereof.
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